List view / Grid view
Enzymes are macromolecular biological catalysts. Enzymes accelerate, or catalyse, chemical reactions.
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes…
Researchers have obtained images with a previously unseen level of detail, demonstrating how RNA polymerase opens the transcription bubble.
The experimental therapy eliminated 90 percent of HSV-1 after facial infection and 97 percent of HSV-1 after genital infection.
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
Inhibiting the LDHA and GOT1 enzymes could prevent cancer cells’ ability to produce energy, without affecting healthy cells.
Treatment with Palbociclib and a compound targeting CAD increased survival to 100 percent for selected lymphoma cell lines.
Scientists have discovered that increasing the levels of the CDKL2 enzyme could stop CDD symptoms developing or worsening.
A mechanism by which the immune system influences central nervous system function and behaviour has been discovered.
Researchers discover a key metabolic process that cancer cells use to grow in a nutrient deprived environment, which could be a new target.
New understanding of the communication system between pathogens and host cells provides a way to avoid antimicrobial resistance.
A discovery about Zika’s enzyme, NS2B-NS3, offers promise for therapeutic targets for Zika and other flaviviruses.
Astrocyte plasticity is correlated with upregulation of the Galectin 3 protein, which may greatly contribute to biomarker discovery.
Researchers found heightened SCAN enzyme activity in humans and mice with diabetes results in excessive nitric oxide on insulin receptors.
Novel findings about the tafazzin gene offers a potential new target and drug candidate for Barth syndrome.
